Should emergency departments offer postexposure prophylaxis for non-occupational exposure to HIV?

CJEM

Volumn 5, Issue 1, 2003, Pages 38-45

  Spence, Julie M ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

antiretroviral therapy; HIV; HIV exposure; non occupational exposure; postexposure prophylaxis

Indexed keywords

EID: 85008561905     PISSN: 14818035     EISSN: 14818043     Source Type: Journal    
DOI: 10.1017/S1481803500008101     Document Type: Article

References (75)

1. Public Health Service guidelines for the management of healthcare worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998; 47(RR-7):1–28. Available: www.cdc.gov/epo/mmwr/preview/mmwrhtml/00052722.htm (accessed 2002 Nov 13).
2. Ippolito G, Puro V, Heptonstall J, Jagger J, De Carli G, Petrosillo N. Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Clin Infect Dis 1999; 28: 365–83.
3. Health Canada. HIV/AIDS Epi Update. Ottawa: Division of HIV/AIDS Epidemiology and Surveillance; April 2002.
4. Management of possible sexual, injection-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy Public Health Service statement. MMWR Morb Mortal Wkly Rep 1998; 47(RR-17):1–14. Available: www.cdc.gov/mmwr/preview/mmwrhtml/00054952.htm (accessed 2002 Nov 8).
5. Preventive therapy for non-occupational exposures to HIV. CDC Divisions of HIV/AIDS Prevention; 2002. Available: www.cdc.gov/hiv/pubs/facts/petfact.htm (accessed 2002 Nov 19).
6. Greenwood MJ. Exposure to HIV: medical management and legal implications. J Emerg Med 2000; 19(3):231–9.
7. DeGruttola V, Seage GR, Mayer KH, Horsburgh CR. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989; 42: 849–56.
8. Jacquez JA, Koopman JS, Simon CP, Longini IM. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immun Defic Syndr 1994; 7: 1169–84.
9. Bamberger JD, Waldo CR, Geberding JL, Katz M. Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault. Am J Med 1999; 106: 3.
10. Wiley JA, Herschkorn SJ, Padian NS. Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile–vaginal intercourse. Stat Med 1989; 8: 93–102.
11. Peterman TA, Stoneburner RL, Allen JR, Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1989; 259: 55–8.
12. Downs MA, De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. J Acquir Immun Defic Syndr Hum Retrovirol 1996; 11: 388–95.
13. Mastro TD. Probabilities of sexual HIV-1 transmission. AIDS 1996; 10(suppl A):S75–82.
14. Katz MH, Gerberding JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med 1998; 128: 306–12.
15. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Synd 1992; 5: 1116–8.
16. Dominguez KL. Management of HIV-infected children in the home and institutional settings. Pediatr Clin North Am 2000; 47 (1):203–39.
17. Richman KM, Rickman LS. The potential for transmission of human immunodeficiency virus through human bites. J Acquir Immune Defic Syndr 1993; 6(4):402–6.
18. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50(RR-11):1–52.
19. Lurie P, Miller S, Hecht F, Chesney M, Lo B. Postexposure prophylaxis after nonoccupational HIV exposure. JAMA 1998; 280 (20):1769–73.
20. American Academy of Pediatrics. Human immunodeficiency virus infection. In: Pickering LK, editor. 2000 Red Book: Report of the Committee on Infectious Disease. Elk Grove Village (IL): 2000. p. 325–50.
21. Aragon Pena AJ, Arrazola Martinez MP, Garcia de Codes A, Davila Alvarez FM, de Juanes Pardo JR. Hepatitis B prevention and risk of HIV infection in children injured by discarded needles and/or syringes. Aten Primaria 1996; 17: 138–40.
22. Nourse CB, Charles CA, McKay M, Keenan P, Butler KM. Childhood needle stick injuries in the Dublin metropolitan area. Irish Med J 1997; 90: 66–9.
23. Rinaldi R, Francavilla E, Cadrobbi P. HIV infection and needlestick injuries with syringes discarded by drug abusers. Infection 1991; 1: 57.
24. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183: 215–25.
25. Zhang ZQ, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286: 1353–7.
26. Blauvelt A. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Am J Med 1997; 102 (5B):16–20.
27. Pope M, Gezelter S, Gallo N, Hoffman L, Steinman RM. Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp Med 1995; 182: 2045–56.
28. Blauvelt A, Katz SI. The skin as target, vector and effect on organ in human immunodeficiency virus disease. J Invest Dermatol 1995; 103: 122S–6S.
29. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270: 1197–9.
30. Tsai CC, Follis KE, Sabo O, Grant R, Bishofberger N. Efficacy of 9-(2-phosphonylmethoxyethyl) adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis 1995; 171: 1338–43.
31. Van Rompay KK, Marthas ML, Ramos RA, Mandell CP, McGowan EK, Joye SM, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992; 36(11):2381–6.
32. Van Rompay KK, Otsyula MG, Marthas ML, Miller CJ, McChesney MB, Pedersen NC. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995; 39(1):125–31.
33. Tavares L, Roneker C, Johnston K, Lehrman SN, deNoronha F. 3'-azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res 1987; 47: 3190–4.
34. Ruprecht RM, Chou CT, Chipty F, Sosa MG, Mullaney S, O'Brien L, et al. Interferon-alpha and 3'-azido-3'-deoxythynmidine are highly synergistic in mice and prevent viremia and after acute retroviral exposure. J Acquir Immune Defic Syndr 1990 (3):591–600.
35. Fazely F, Haseltine WA, Rodger RF, Ruprecht RM. Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr 1991; 4: 1093–7.
36. Henderson DK. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 1999; 281(10):931–6.
37. Katz MH, Gebererding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection drug use. N Engl J Med 1997; 336(15):1097–100.
38. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994; 271(1):42–6.
39. Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med 1997; 102(5B):21–4.
40. D'Amico R, Pinto LA, Meyer P, Landay AL, Harris AA, Clerici M, et al. Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers. Infect Control Hosp Epidemiol 1999; 20: 428–30.
41. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case–control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group [see comments]. N Engl J Med 1997; 337(21):1485–90.
42. Mangione CM, Gerberding JL, Cummings SR. Occupational exposure to HIV: frequency and rates of underreporting of percutaneous and mucocutaneous exposures by medical housestaff. Am J Med 1991; 90: 85–90.
43. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998; 280: 78–86.
44. Fournier S, Maillard A, Molinara JM. Failure of postexposure prophylaxis after sexual exposure to HIV. AIDS 2001; 15(3):430.
45. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal–infant transmission of human immunodeficiency virus Type I with zidovudine treatment. N Engl J Med 1994; 331(18):1173–80.
46. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission, Thailand, 1996–1998. MMWR Morb Mortal Wkly Rep 1998; 47: 151–4.
47. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353: 773–80.
48. Wade NE, Birkhead GS, Warren BL, Charbonneau TT, French T, Wang L, et al. Abbreviated regimens for zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339(20):1409–14.
49. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479–86.
50. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 Randomized Trial. Lancet 1999; 354: 795–802.
51. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS 2002; 16(3):397–405.
52. Puro V, De Carli G, Orchi N, Palvarini L, Chiodera A, Fantoni M, et al. Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. J Bio Regul Hemost Agents 2001; 15(3):238–42.
53. Kahn JG, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183: 707–14.
54. Cardo D, Danila R, Deitchman S, Jensen P, Middleton J, Panlilio A, et al, for the HIV PEP Registry Advisory Committee. The HIV Postexposure Prophylaxis Registry. Registry of health-care workers receiving postexposure prophylaxis after occupational exposure to human immunodeficiency virus. Final report: 17 October 1996 through 31 March 1999. Centers for Disease Control and Prevention, Glaxo Wellcome Inc, Merck & Co., Inc.; 1999 March 31. Available: www.cdc.gov/ncidod/hip/BLOOD/PEPRegistry.pdf (accessed 2002 Nov 19).
55. Beekman SE, Nelson L, Bangsberg D, Henderson DK, Gerberding JL. Combination post-exposure prophylaxis (PEP): a prospective study of HIV-exposed health care workers (HCW) [poster]. Infectious Diseases Society of America, Denver (CO); 1998.
56. Parkin JM, Murphy M, Anderson J, ElGadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355: 722–3.
57. Wang SA, Panlilio AL, Doi PA, White AD, Stek M Jr, Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000; 21: 780–5.
58. Garb JR. One-year study of occupational human immunodeficiency virus postexposure prophylaxis. J Occup Environ Med 2002; 44(3):265–70.
59. Rabaud C, Bevilacqua S, Beguinot I, Dorvaux V, Schumhmacher H, May T, et al. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 1494–5.
60. Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers [letter]. JAMA 2000; 284(21):2723.
61. Johnson S, Baraboutis JG. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers [letter]. JAMA 2000; 284(21):2722.
62. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures – worldwide, 1997–2000. MMWR Morb Mortal Wkly Rep 2001; 49: 1153–6.
63. Rey D, L'Heritier A, Lang JM. Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV. Clin Infect Dis 2002; 34: 418.
64. Greub G, Gallant S, Zurn P, Vannotti M, Burgisser P, Francioli P, et al. Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person. AIDS 2002; 16(8):1171–6.
65. HIV and sexual violence against women. Health Canada; 2000. Available: www.hc-sc.gc.ca/hppb/hiv_aids/you/sex_violence/risk.html (accessed 2002 Nov 19).
66. Busch MP. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102(5B):117–24.
67. Lurie P, Miller S, Hecht F, Lo B. Postexposure prophylaxis following HIV exposure. JAMA 1999; 281(14):1270.
68. Kalichman SC. Post-exposure prophylaxis for HIV infection in gay and bisexual men: implications for the future of HIV prevention. Am J Prev Med 1998; 15(2):120–7.
69. Kunches LM, Meehan TM, Boutwell RC, McGuire JF. Survey of nonoccupational HIV postexposure prophylaxis in hospital emergency departments. J Acquir Immun Defic Syndr 2001; 26 (3):263–5.
70. Giele CM, Maw R, Carne CA, Evans BG. Post-exposure prophylaxis for non-occupational exposure to HIV: current clinical practice and opinions in the UK. Sex Transm Infect 2002; 78(2):130–2.
71. Babl FE, Cooper ER, Kastner B, Kharasch S. Prophylaxis against possible human immunodeficiency virus exposure after nonoccupational needlestick injuries or sexual assaults in children and adolescents. Arch Pediatr Adolesc Med 2001; 155: 680–2.
72. HIV/AIDS among men who have sex with men. Division of HIV/AIDS Surveillance, Bureau of HIV/AIDS, STD and TB, LCDC, Health Canada; 1999.
73. Gostin LO, Lazzarini Z, Alexander D, Brandt AM, Mayer KH, Silverman DC. HIV testing, counseling, and prophylaxis after sexual assault. JAMA 1994; 271(18):1436–44.
74. Wiebe ER, Comay SE, McGregor MJ, Ducceschi S. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. CMAJ 2000; 162(5):641–5.
75. Myles JE, Hirozawa A, Katz M, Kimmerling R, Bamberger JD. Postexposure prophylaxis for HIV after sexual assault. JAMA 2000; 284(12):1516–7.